Chronic Lymphocytic Leukemia

Featured

News
Acalabrutinib Improves PFS and OS Over Other First-Line Regimens in CLL
Acalabrutinib demonstrated favorable PFS and OS compared with standard first-line treatments for CLL, according to a systematic review and network meta-analysis.
Quiz
Quiz: First-line Treatments for Patients With Chronic Lymphocytic Leukemia
True or False: First-line acalaburitnib plus obinutuzmumab prolongs progression-free survival compared to ibrutinib-…
Videos
Physician Testimonial With Dr. Graff (Sponsored)
Tara Graff, DO, explains how the introduction of acalabrutinib has impacted the treatment of CLL.
Videos
Physician Testimonial With Dr. Danilov (Sponsored)
Alexey Danilov, MD, PhD, discusses acalabrutinib as a treatment option for patients with CLL, SLL, and MCL.
News
Acalabrutinib Plus Obinutuzumab Prolongs PFS Compared to Other Targeted Agents in CLL
First-line acalaburitnib plus obinutuzmumab prolongs PFS compared to ibrutinib-obinutuzumab and venetoclax-obinutuzumab…

News

Acalabrutinib Improves PFS and OS Over Other First-Line Regimens in CLL
Acalabrutinib Plus Obinutuzumab Prolongs PFS Compared to Other Targeted Agents in CLL
Ibrutinib Associated With Significant Cost Savings vs Chemoimmunotherapy for CLL/SLL
First-Line Bendamustine Plus Rituximab Safe, Effective for Unfit Patients With CLL

Guideline Updates

NCCN Updates Clinical Practice Guidelines for CLL/SLL

Interviews

Front-Line Therapy for CLL: Long-Term Follow-Up of Time to Next Treatment, HRU

Blog

What is the Most Appropriate First-Line Treatment in CLL?

Videos

Physician Testimonial With Dr. Graff (Sponsored)

Podcast

First-Line Ibrutinib Effective for CLL/SLL Irrespective of Cytogenetic or Mutational Risk Features